Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/07 10:06:08 am
272.445 USD   +2.68%
07:45aMarketScreener's World Press Review - December 7, 2021
07:16aEU agencies endorse mix-and-match of COVID-19 vaccines
RE
06:46aREFILE-EU health bodies recommend mix-and-match of COVID-19 vaccines
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : FDA scientists' analysis of J&J COVID-19 booster data raises red flags

10/13/2021 | 04:03pm EST

Oct 13 (Reuters) - U.S. Food and Drug Administration scientists said on Wednesday they did not receive enough data in time to do their own analysis of Johnson & Johnson's application for a booster dose of its COVID-19 vaccine, but the agency's review of company studies raised some red flags.

Advisers to the FDA will meet on Oct. 15 to assess the risks and benefits of a booster shot of J&J's vaccine, which is currently given as a single dose.

In its review, FDA scientists repeatedly noted the limitation of small sample sizes of many of the company's studies.

They noted that data J&J used to support administering a booster six months after the initial shot relied on a test to measure immune response that has not been validated and was possibly not sensitive enough.

That mismatch in assessment tools would make it challenging to make meaningful comparisons with data from the company's larger two-dose booster trial.

Agency scientists also noted that there were insufficient cases of COVID-19 caused by the Delta variant to estimate how effective the vaccine is against the coronavirus mutation now dominant globally in that larger J&J trial evaluating two doses of the vaccine given nearly two months apart.

U.S. health officials have been under pressure to offer advice on booster doses of the J&J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults, pending approvals from the FDA and the U.S. Centers for Disease Control and Prevention (CDC).

The FDA and CDC last month signed off on boosters https://www.reuters.com/world/us/us-cdc-advisers-recommend-covid-19-vaccine-boosters-65-older-high-risk-2021-09-23 of the Pfizer Inc and BioNTech SE COVID-19 vaccine for certain high-risk adults, but reviews of the Moderna and J&J shots were delayed until the companies could produce more data.

The FDA on Tuesday released its assessment https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-seeks-covid-19-vaccine-booster-clearance-older-adults-high-risk-2021-10-12 of Moderna's booster application ahead of a meeting of expert advisers on the topic on Thursday. Neither assessment made a recommendation to the panel on whether the data supports use of booster shots.

Independent vaccine experts at the meeting on Friday will hear presentations from the FDA and J&J scientists, and be asked whether company data supports use of a booster dose at least two months after the initial shot. They also will be asked to assess whether a J&J booster given six months after the first shot may result in a more robust immune response. (Reporting by Julie Steenhuysen in Chicago and Manas Mishra in Bengaluru; Editing by Anil D'Silva and Bill Berkrot)


ę Reuters 2021
All news about MODERNA, INC.
07:45aMarketScreener's World Press Review - December 7, 2021
07:16aEU agencies endorse mix-and-match of COVID-19 vaccines
RE
06:46aREFILE-EU health bodies recommend mix-and-match of COVID-19 vaccines
RE
06:23aCowen Starts Moderna at Market Perform With $250 Price Target
MT
12/06AstraZeneca, Pfizer-BioNTech's COVID-19 Jabs Work Well With Moderna Shot, UK Study Says
MT
12/06Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response -UK stud..
RE
12/06Health Care Up As Moderna Slides -- Health Care Roundup
DJ
12/06Wall Street regains some ground with help from easing virus fears
RE
12/06US Indices Rebound on Indications Omicron Less Severe Than Previously Anticipated; Trea..
MT
12/06Delta, Kohl's rise; Moderna, AST SpaceMobile fall
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 505 M - -
Net income 2021 11 217 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 10,1x
Yield 2021 -
Capitalization 108 B 108 B -
EV / Sales 2021 5,44x
EV / Sales 2022 4,08x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 265,33 $
Average target price 271,13 $
Spread / Average Target 2,18%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888
ICON PUBLIC LIMITED COMPANY36.39%21 647